COEP — Coeptis Therapeutics Holdings Income Statement
0.000.00%
Last trade - 00:00
- $10.62m
- $11.92m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | — | 0.181 | 0.681 | 34.2 | 21.5 |
Operating Profit | 0 | -0.181 | -0.681 | -34.2 | -21.5 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.002 | -17.3 | 15.2 | -37.6 | -21.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.002 | -17.3 | 15.2 | -37.6 | -21.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.002 | -17.3 | 15.2 | -37.6 | -21.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.002 | -17.3 | 15.2 | -37.6 | -21.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0 | -1.83 | 1.62 | -2.63 | -0.828 |
Dividends per Share |